ReviewWorld journal of gastroenterology2015
Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease.
Review in World journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Phage Therapy in Gastrointestinal Diseases: Current Status and Challenges.International journal of molecular sciences · 2026Review
- Insight into Bacteriophage Therapy for Bacterial Infections and Cancer.Molecular biotechnology · 2026Review
- Gut virome: New key players in the pathogenesis of inflammatory bowel disease.World journal of methodology · 2025Review
- Characterization and therapeutic potential of newly isolated bacteriophages targeting the most common Salmonella serovars in Europe.Scientific reports · 2025Article
- Intestinal mucosal immunity and type 1 diabetes: Non-negligible communication between gut and pancreas.Diabetes, obesity & metabolism · 2025Review
- Gut virome and diabetes: discovering links, exploring therapies.Archives of microbiology · 2024Review
- Both viableMicrobiology spectrum · 2024Article
- Kidney Diseases Associated With Inflammatory Bowel Disease: Impact of Chronic Histologic Damage, Treatments, and Outcomes.Kidney international reports · 2024Article
- Exploring the Connections: Autophagy, Gut Microbiota, and Inflammatory Bowel Disease Pathogenesis.Journal of inflammation research · 2024Review
- Microscopic messengers: microbiota-derived bacterial extracellular vesicles in inflammatory bowel disease.Frontiers in microbiology · 2024Review
- Inactivation ofCurrent research in food science · 2024Article
- Association Between Inflammatory Bowel Disease and Viral Infections.Current microbiology · 2023Review
- Review
- Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Glucagon-like peptide (GLP) -2 improved colonizing bacteria and reduced severity of ulcerative colitis by enhancing the diversity and abundance of intestinal mucosa.Bioengineered · 2021Article
- Review
- Roles of Gut Bacteriophages in the Pathogenesis and Treatment of Inflammatory Bowel Disease.Frontiers in cellular and infection microbiology · 2021Review
- The Presence of Bacteriophages in the Human Body: Good, Bad or Neutral?Microorganisms · 2020Review
- Review
- Application of bacteriophages to controlIranian journal of veterinary research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The intestinal microbiome is a dynamic system of interactions between the host and its microbes. Under physiological conditions, a fine balance and mutually beneficial relationship is present. Disruption of this balance is a hallmark of inflammatory bowel disease (IBD). Whether an altered microbiome is the consequence or the cause of IBD is currently not fully understood. The pathogenesis of IBD is believed to be a complex interaction between genetic predisposition, the immune system and environmental factors. In the recent years, metagenomic studies of the human microbiome have provided useful data that are helping to assemble the IBD puzzle. In this review, we summarize and discuss current knowledge on the composition of the intestinal microbiota in IBD, host-microbe interactions and therapeutic possibilities using bacteria in IBD. Moreover, an outlook on the possible contribution of bacteriophages in the pathogenesis and therapy of IBD is provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.